Nicholas Stewart Dean

Nicholas Stewart Dean

Auto-generated profile, based on publicly available information

Nicholas Stewart Dean

Division of Urology, Department of Surgery, University of Alberta, Edmonton, Canada

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Journal of Urology
Verified
Journal Article
Closed access
NDNicholas S. Dean
Nicholas S. Dean
BMBraden Millan
Braden Millan
MUMichael Uy
Michael Uy
PAPatrick Albers
Patrick Albers
SCSandra M. Campbell
Sandra M. Campbell
SDShubha De
Shubha De
Ureteral stone impaction is associated with unfavorable endourologic outcomes, however reliable predictors of stone impaction are limited. We aimed to assess the performance of ureteral wall thickness (UWT) on non-contrast computed tomography as a predictor of ureteral stone impaction and failure rates of spontaneous stone passage, shockwave lithotripsy, and retrograde guidewire and stent passage. This study was completed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines (PRISMA). A search was conducted in April 2022 for all adult, human and English language studies investigating UWT using PROSPERO, OVID Medline, OVID EMBASE, Wiley Cochrane Library, Proquest Dissertations and Theses Global and SCOPUS. A systematic review and meta-analysis using random effects model were conducted. Risk of bias was assessed using the MINORS score. Fourteen studies with a pooled population of 2987 patients were included for quantitative analysis and 34 studies were included in our qualitative review. Meta-analysis findings suggest that a thinner UWT is associated with more favorable subgroup stone outcomes. Thinner UWT suggests a lack of stone impaction and was associated with improved rates of spontaneous stone passage, successful retrograde guidewire and stent placement, and improved shockwave lithotripsy outcomes. Studies lack a standardized UWT measurement protocol. UWT is a non-invasive measure that predicts ureteral stone impaction and thin measurements are predictive of successful outcomes. Variability in measurement methods confirms that a standardized UWT protocol is needed, and the clinical utility of UWT is yet to be determined.

1 February 2023 in Journal of Endourology
Verified
Journal Article
Closed access
NDNick Stewart Dean
Nick Stewart Dean
AKAmy E. Krambeck
Amy E. Krambeck
Introduction: Endourologic procedures, including ureteroscopy (URS) and percutaneous nephrolithotomy (PCNL), are associated with an elevation in intrarenal pressures (IRPs) and irrigation temperatures. Recent research has focused on methods to reduce IRP and irrigation temperatures, with the ultimate goal to limit the consequences associated with these deviations. The purpose of our study is to provide a narrative review on the effects of endourologic procedures on pressure and temperature and provide recommendations to minimize these changes. Methods: A literature review was performed using PubMed. The search was limited to English human and nonhuman studies. Abstracts were reviewed for inclusion in our narrative review. Results: Human and animal models suggest that URS and PCNL are associated with peak IRPs above a “safe” threshold. Strategies to minimize pressures focus on minimizing irrigation flow into the upper tract and maximizing flow out of the system. High IRP has been associated with postoperative pain and infectious complications. Elevated irrigation temperatures are associated with high-power lasers during URS. Strategies to minimize irrigation temperatures focus on maximizing irrigation flow during laser activation and minimizing thermal energies associated with lithotripsy. Conclusions: Rises in pressure and irrigation temperatures associated with endourologic procedures are becoming increasingly recognized in the urologic community. Human studies examining “safe” thresholds for IRP and irrigation temperatures are limited. Temperature- and pressure-sensing technologies will aid in identifying the clinical consequences of elevated IRPs and irrigation temperatures, resulting in strategies to minimize them.

1 October 2023 in Journal of Endourology
Verified
Journal Article
Closed access
JGJenny N. Guo
Jenny N. Guo
NMNeil A. Mistry
Neil A. Mistry
MLMatthew S. Lee
Matthew S. Lee
NDNicholas Stewart Dean
Nicholas Stewart Dean
MAMark Assmus
Mark Assmus
AKAmy Krambeck
Amy Krambeck
INTRODUCTION: Holmium laser enucleation of the prostate (HoLEP) has evidenced-based advantages in treating benign prostatic hypertrophy (BPH) relative to other interventions. Unfortunately, adoption of HoLEP has remained relatively low in Medicare and National Surgical Quality Improvement Program (NSQIP) populations. HoLEP’s role as an inpatient surgical intervention is changing as advancements in the technique and systems have demonstrated the feasibility of same-day discharge. Thus, our objective was to evaluate national HoLEP trends in ambulatory surgery settings from 2016-2019. METHODS: The Nationwide Ambulatory Surgery Sample (NASS) is the largest national all-payer database of ambulatory surgical encounters, managed by the Agency for Healthcare Research and Quality. A cross-sectional, retrospective analysis of the 2016 and 2019 NASS was performed. Rates of BPH surgeries were calculated and stratified by age, census region, and primary payer to compare across time-points for trends. Chi-squared and two-sample t-tests were completed for categorical and continuous variables, respectively. RESULTS: The total number of ambulatory BPH surgeries fell 20% between 2016 (n=124,538) and 2019 (n=100,593). In 2016, HoLEP lagged behind photo-selective vaporization of the prostate (PVP) and Transurethral Resection of Prostate (TURP) with 4.7% of surgeries, but rose to the second most-common procedure in 2019 with 8.3% of total surgeries. TURP was the most common intervention (62.6% in 2016, 90.7% in 2019). Simple prostatectomy was the most expensive intervention. By US census region, more HoLEPs were done in the South (43.1% in 2016, 37.5% in 2019) and Midwest (26.8% in 2016, 31.7% in 2019). CONCLUSION: Overall, HoLEP uptake is increasing. HoLEP has replaced greenlight PVP as the second-most frequently used intervention. The rate of ambulatory HoLEPs has nearly doubled despite a general decrease in the number of surgeries.

1 December 2023 in Journal of Endourology
Verified
Journal Article
Closed access
NDNicholas Stewart Dean
Nicholas Stewart Dean
MLMatthew S. Lee
Matthew S. Lee
MAMark Assmus
Mark Assmus
JGJenny N. Guo
Jenny N. Guo
PXPerry Xu
Perry Xu
AKAmy Krambeck
Amy Krambeck
Introduction: Holmium laser enucleation of the prostate (HoLEP) is routinely performed with a 24, 26, or a 28 French (F) scope. Proponents of the larger scopes propose that a bigger sheath size allows for superior flow and visibility leading to a more efficient operation and better hemostasis. Those utilizing the smaller scopes suggest the lower profile is less traumatic, resulting in lower stricture rates and temporary incontinence. We sought to compare outcomes of ambulatory HoLEP using the 24F and 28F laser scope. Materials and Methods: From May 2022 to March 2023, we randomized patients undergoing HoLEP (0.05) scopes. Procedural duration and efficiencies were not different between groups (all p>0.05). The 28F scope was associated with improved surgeon-graded irrigation flow and visibility (p0.05). Conclusions: We identified no clear advantage of scope size with regards to intra-operative or post-operative outcomes at 3-month follow up due to scope size. However, if same-day discharge is part of your postoperative pathway, the 28F scope may shorten length of stay and increase rates of successful same-day trial of void.

21 July 2023 in Canadian Urological Association Journal
Verified
Journal Article
Closed access
PDF file
NDNicholas S. Dean
Nicholas S. Dean
MAMark A. Assmus
Mark A. Assmus
MLMatthew S. Lee
Matthew S. Lee
JGJenny N. Guo
Jenny N. Guo
AKAmy E. Krambeck
Amy E. Krambeck
Introduction: Prostatic urethral lift (PUL) accounts for approximately one-quarter of all surgical benign prostatic hyperplasia (BPH) procedures performed in the U.S.1 Within five years of a patient’s PUL procedure, approximately 1/7 patients will require surgical BPH re-treatment.2 We aimed to highlight the evidence of surgical BPH re-treatment modalities after PUL, with a focus on safety, short-term efficacy, durability, and relative costs. Methods: A literature review was performed using PubMed, and an exhaustive review of miscellaneous online resources was completed. The search was limited to English, human studies. Citations of relevant studies were reviewed. Results: No study has examined the efficacy, safety, or durability of transurethral resection of the prostate (TURP) or repeat PUL in the post-PUL setting. Recently, groups have examined laser enucleation (n=81), water vapor thermal therapy (WVTT) (n=5), robotic simple prostatectomy (SP) (n=2), and prostatic artery embolization (PAE) (n=1) in the post-PUL setting. Holmium enucleation of the prostate (HoLEP) after PUL appears to be safe and has similar functional outcomes to HoLEP controls. Other treatment modalities examined appear safe but have limited efficacy evidence supporting their use. Photo-selective vaporization of the prostate (PVP) and robotic waterjet treatment (RWT) have no safety or efficacy studies to support their use in the post-PUL setting. Conclusions: Despite increasing numbers of patients expected to require surgical re-treatment after PUL in North America, there is currently limited evidence and a lack of recommendations guiding the evaluation and management of these patients. HoLEP is associated with the strongest evidence to support its use in the post-PUL setting.

8 May 2023 in Journal of Endourology
Verified
Journal Article
Closed access
MHMitchell M. Huang
Mitchell M. Huang
NDNicholas Stewart Dean
Nicholas Stewart Dean
MAMark Assmus
Mark Assmus
MLMatthew S. Lee
Matthew S. Lee
JGJenny N. Guo
Jenny N. Guo
AKAmy Krambeck
Amy Krambeck
Introduction: Intradetrusor onabotulinumtoxinA (OTA) injection is a well-established treatment option for refractory overactive bladder (OAB), however its use at the time of holmium laser enucleation of the prostate (HoLEP) for men with bladder outlet obstruction (BOO) and storage symptoms has not been previously reported. Material and Methods: We retrospectively identified men with BOO and OAB who underwent treatment with 200U of intradetrusor OTA at the time of HoLEP. Patients were propensity score matched to a cohort of HoLEP-only patients based on age, Michigan Incontinence Symptom Index (M-ISI) score, pre-operative urinary retention, urge incontinence, and prostate size. Perioperative, post-operative, and patient-reported outcomes were examined between groups. Results: We identified 82 men who underwent HoLEP, including 41 patients in the OTA group and 41 patients in the control group. There was no difference in operative times (59 mins OTA vs 55 mins control, p=0.2), rates of successful same-day TOV (92% OTA vs. 94% control, p=0.7), or rates of same-day discharge (88% OTA vs. 85% control, p=0.6) between groups. There was no difference in temporary post-operative urinary retention (7% OTA vs. 2% control, p=0.3) between groups. Patients who received OTA injections had a significant reduction in their incontinence scores at 3-month follow-up (M-ISI -8, IQR: -13 to 0, p<0.001), while control patients did not (M-ISI -5, IQR: -8 to -1, p=0.2). There was no difference in rates of 90-day complications between groups (OTA 10% vs. control 5%, p=0.7). Conclusions: Intradetrusor OTA at the time of HoLEP is safe and is associated with improved urinary incontinence scores and AUA Symptom Score (AUASS). Rates of same-day discharge and successful same day TOV after HoLEP were not affected by OTA. These findings support the role of OTA as an adjunct to surgical intervention in men with incontinence related to OAB in the presence of BOO.